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Abstract
Severe side effects often restrict clinical application of the widely used chemotherapeutic drug doxorubicin. In order to
decrease required substance concentrations, new concepts for successful combination therapy are needed. Since
doxorubicin causes DNA damage, combination with compounds that modulate DNA repair could be a promising
strategy. Very recently, a role of nuclear actin for DNA damage repair has been proposed, making actin a potential
target for cancer therapy in combination with DNA-damaging therapeutics. This is of special interest, since actin-
binding compounds have not yet found their way into clinics. We ﬁnd that low-dose combination treatment of
doxorubicin with the actin polymerizer chondramide B (ChB) synergistically inhibits tumor growth in vivo. On the
cellular level we demonstrate that actin binders inhibit distinctive double strand break (DSB) repair pathways. Actin
manipulation impairs the recruitment of replication factor A (RPA) to the site of damage, a process crucial for
homologous recombination. In addition, actin binders reduce autophosphorylation of DNA-dependent protein kinase
(DNA-PK) during nonhomologous end joining. Our ﬁndings substantiate a direct involvement of actin in nuclear DSB
repair pathways, and propose actin as a therapeutic target for combination therapy with DNA-damaging agents such
as doxorubicin.
Introduction
The anthracycline doxorubicin (Doxo) is widely used for
therapy of a broad range of cancer types. However, like
any other chemotherapy, treatment with Doxo induces
unwanted side effects (e.g. cardiovascular morbidity due
to both acute and delayed cardiotoxicity1,2). Nevertheless,
Doxo is still an indispensable part of cancer therapy. To
increase therapeutic effectiveness while reducing unwan-
ted adverse effects, combination therapy concepts have to
be developed.
One mode of action of Doxo is to stabilize the
topoisomerase II complex during DNA replication,
which induces DNA double strand breaks (DSB) and
promotes apoptosis3,4. Cells respond to such DNA
damage by starting various repair mechanisms. Target-
ing speciﬁc proteins involved in these DNA repair
pathways (repair factors) has been suggested as a pro-
mising approach for cancer therapy. DSBs can be
repaired by different repair pathways, depending on the
functional context of the cell. Nonhomologous end
joining (NHEJ) works independently of sequence
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homology and cell cycle. During NHEJ, DNA-dependent
protein kinase (DNA-PK) is formed by binding of its
catalytic subunit (DNA-PKcs) to a DNA-bound Ku70/80
heterodimer, leading to its activation. Activated DNA-
PK phosphorylates itself and other targets involved in
NHEJ5–7. The other DSB repair pathways depend on
DNA end resection, i.e. the generation of single stranded
DNA (ssDNA). Alternative end joining (alt-EJ) utilizes
PARP-1-mediated annealing at short homologous DNA
sequences (microhomologies)8,9. Homology directed
repair (HDR) and single strand annealing (SSA), how-
ever, both depend on extensive end resection, as repli-
cation factor A (RPA)—a crucial initiation factor for
both pathways—can only bind to ssDNA. During HDR,
RPA mediates Rad51-dependent strand invasion of
intact homologous regions on the sister chromatid
during S-phase for accurate repair10–12. SSA anneals
homologous repeat sequences that ﬂank the DSB, which
is facilitated by Rad52 bound to the ssDNA-RPA com-
plexes12–14.
Surprisingly, sufﬁcient nuclear levels of actin and its
ability to polymerize have been suggested to be required
for efﬁcient repair of irradiation or UV-induced DNA
damage15,16. It seems that DSBs have to be actively clus-
tered in an actin-dependent way during the G1 phase of
the cell cycle before being repaired in the G2 phase17.
Very recently, nuclear Arp2/3 complex18,19 and myosins18
have been identiﬁed as crucial factors for actin-dependent
mobility of DSBs for efﬁcient repair by HDR. To date,
these mechanisms have been investigated mainly in model
systems that can be tightly controlled to allow for max-
imum mechanistic insight. However, the role of actin in
the DNA damage repair processes in a complex and more
clinically relevant setting is far from being understood. As
the obvious requirement of actin during DSB repair sug-
gests actin as an attractive target for combination therapy
with DNA-damaging substances, we used two classes of
actin-binding compounds: polymerizers, such as jaspla-
kinolide (Jaspla)20 or chondramide B (ChB)21, and a
depolymerizer, like latrunculin B (LB)22 in combination
with the clinically relevant drug Doxo. Despite the fact
that actin binders alone have shown antitumor char-
acteristics in different experimental setups23–25, actin is
not directly targeted yet for clinical application due to
toxicity issues.
In this study we show that combination of subtoxic
doses of actin-binding substances with classical che-
motherapy is possible and leads to synergistic effects on
tumor growth in vivo. We demonstrate the failure of DSB
repair due to actin manipulation after Doxo-induced
DNA damage, both in vitro and in vivo. On a molecular
level, we describe inhibition of RPA recruitment during
HDR and SSA, as well as decreased autophosphorylation
of DNA-PK during NHEJ. We propose DNA repair
inhibition by application of actin binders as a novel
strategy for combination therapy with the DNA-damaging
agent doxorubicin.
Materials and methods
Cell culture
MDA-MB-231 cells were purchased from CLS (Eppel-
heim, Germany), 4T1-luc2 (mouse) from Caliper-
PerkinElmer (Alameda, CA, USA), T24 and HeLa from
DSMZ (Braunschweig, Germany). U2OS reporter cells26
were kindly provided by Jeremy M. Stark (Beckman
Research Institute of the City of Hope, USA). MDA-MB-
231 and HeLa were cultured in DMEM (Dulbecco´s
Modiﬁed Eagle Medium), T24 and U2OS in McCoy’s 5A
medium, 4T1 cells in RPMI. Media were purchased from
PAA Laboratories (Pasching, Austria). All cells were cul-
tivated with 10% FCS (fetal calf serum) and 1% penicillin/
streptomycin (Sigma-Aldrich) and were grown at 37 °C,
5% CO2. HeLa cells were tested for mycoplasma every
fourth month. Cells were not used for more than 15
passages after thawing.
Reagents
Jasplakinolide (Jaspla) was purchased from R&D Sys-
tems (Bio-Techne GmbH, Wiesbaden, Germany) and
Latrunculin B (LB) from Sigma-Aldrich (Taufkirchen,
Germany). Chondramide B (ChB) was isolated as descri-
bed previously27. Doxorubicin hydrochloride (Doxo) was
purchased from Sigma-Aldrich (Taufkirchen, Germany).
Antibodies are listed in Supplementary information.
In vivo mouse models
All animal experiments were approved by the Govern-
ment of Upper Bavaria in accordance with the German
Animal Welfare and Institutional guidelines.
Tumor growth model
5 × 106 MDA-MB-231 cells were injected sub-
cutaneously into the ﬂank of SCID mice (C.B-17/Icr-
HanHsd-Prkdcscid, Harlan Laboratories, USA). Forty
mice were divided equally into four treatment groups:
solvent (DMSO), two single groups treated intravenously
either with Doxo 1.5 mg/kg body weight (once a week) or
ChB 0.6 mg/kg body weight (thrice a week) and a com-
bination treatment group.
In vivo comet
1 × 106 4T1-luc cells were injected subcutaneously into
BALB/cOlaHsd mice (Envigo, Netherlands) and tumors
grown for 7–9 days. Mice were then treated with 3 mg/kg
Doxo i.v. or in combination with 0.1 mg/kg LB i.p. for 24
h. Tumors were harvested, single-cell suspensions pre-
pared and cells seeded accordingly for alkaline comet
assay.
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Staining of tumor sections
Tumors were removed, ﬁxed in formalin and embedded
in parafﬁn. Sections were stained with anti-Ki67 antibody
(Abcam, USA) and visualized with the Vectastain ABC Kit
(Vector Laboratories, USA) according to the manu-
facturer’s instructions. Images were taken on an Olympus
BX41 microscope (Olympus, Center Valley, PA, USA).
Ki67-positive cells were counted with ImageJ (National
Institute of Health (NIH), USA) and normalized to the
total number of cells.
Alkaline comet assay
For quantiﬁcation of DNA strand breaks, alkaline comet
assay (single-cell electrophoresis) was performed as
described in the Supplementary information.
Fluorescence correlation spectroscopy
FCS measurements were performed on a Leica TCS SP8
SMD. Cells were transfected with Actin-GFP (addgene
21948) using FuGENE® HD (Promega, Mannheim, Ger-
many) 24 h before the FCS measurement. The effective
volume (Veff) and structure parameter (κ) were measured
before each experiment using 1 nM ATTO488 dye solu-
tion (ATTO-TEC GmbH, Siegen, Germany). For every
nucleus three different points were measured (45 s per
point). After the zero-time point measurement, Doxo
[250 nM] was added. FCS curves were analyzed with the
Picoquant SymPhoTime V 5.2.4.0 software and ﬁtted with
a single diffusing species and a triplet state.
I-SceI-based reporter cells
FACS analysis of U2OS cells harboring I-SceI-based
reporter systems was performed as described previously26.
Brieﬂy, U2OS cells were transfected with pCBASceI
plasmid (addgene 26477) using FuGENE® HD for 6 h, and
cells then treated with the indicated actin binders. DMSO
treatment served as positive, untransfected cells as nega-
tive control. After 72 h cells were harvested and ﬂow
cytometry analysis of GFP-positive cells performed on a
FACSCanto™ II (BD Biosciences, Heidelberg, Germany).
Duolink® assay
After treatment of cells with the indicated substances or
transfection with actin plasmids YFP-NLS-Beta-Actin
(addgene 60613), YFP-NLS-Beta-Actin-G13R (addgene
60615), YFP-NLS-Beta-Actin-S14C (addgene 60614),
Duolink® assay was performed according to the provider
(Sigma Aldrich, Taufkirchen, Germany). The detailed
procedure is described in the Supplementary information.
Life cell imaging of actin
For life cell imaging of cells, a stage top incubator (Okolab,
Pozzuoli, Italy) was installed on a Leica TCS SP8 SMD. To
visualize actin cells were transfected with actin-GFP
(addgene 21948), actin-mCherry (addgene 54966), or
nuclear actin-Chromobody® (ChromoTek GmbH, Planegg-
Martinsried, Germany) using FuGENE® HD.
Foci formation assay
Treated cells were ﬁxed with 4% PFA (paraformalde-
hyde), permeabilized with 0.2% Triton X-100, incubated
in primary and secondary antibodies and costained for
actin and nuclei with rhodamine phalloidin (Thermo
Fisher Scientiﬁc) and Hoechst (Thermo Fisher Scientiﬁc),
respectively. Foci were either counted manually or with
the FindFociGUI (ImageJ) plugin.
Chromatin association assay
Chromatin association was measured as described pre-
viously28. In short, HeLa cells were treated with Doxo for
2 h alone or in combination with the respective actin
substance and harvested in cold PBS. Cells were resus-
pended in extraction buffer (0.2% Triton X-100) and
incubated on ice for 5–10 min, washed and ﬁxed with 4%
PFA. Fixed cells were incubated in primary antibodies,
washed once and incubated with the secondary anti-
bodies, washed again and FACS analysis performed.
Flow cytometry
Cell death was determined by YoPro (Thermo Fisher
Scientiﬁc) exclusion assay. Treated cells were harvested
and stained with 1 µM YoPro. YoPro-positive cells were
detected by ﬂow cytometry on a BD FACSCanto II Flow
Cytometer. To analyze the impact of combination therapy
on cell cycle arrest, 7-AAD (Thermo Fisher Scientiﬁc) was
applied. Cells were plated in 12-well plates (1 × 105 cells/
well) and cultured for 24 h followed by treatment with
Doxo and the respective actin substances. After 48 h cells
were harvested and mixed with 250 µl methanol at 4 °C.
Fixed cells were washed once more with PBS, resus-
pended and stained with 7-AAD according to the man-
ufacturer’s instructions. In an FSC/SSC plot cell debris
was excluded, then cell aggregates of two or more cells
were removed and cell cycle phases were analyzed with
FlowJo software (Tree star Inc., Ashland, OR, USA).
Western blot and coimmunoprecipitation
Western blot was performed according to the pre-
viously published protocol29. For coimmunoprecipita-
tion cells were lysed in hypotonic buffer, followed by
nuclear lysis. Protein lysates were incubated in pulldown
antibody for 2 h at 4 °C and beads (Protein A/G PLUS,
Santa Cruz; normal mouse antibody (CST) and beads
without antibody served as control) added for one more
hour. Beads were washed with nuclear lysis buffer and
SDS-PAGE performed. Buffer recipes are listed in
the Supplementary information. ChemiDoc™ Touch
Imaging (Bio-Rad) System was used for detection.
Pﬁtzer et al. Cell Death and Disease          (2019) 10:302 Page 3 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
Quantiﬁcation of protein amount was done by Image
LabTM Software (Bio-Rad).
RPA-2/actin-binding structure model
Structure modeling of the RPA-2/actin protein−protein
interaction was performed with HHpred, PredUs, SPPI-
DER, ConSurf -, ClusPro, and RosettaDock as described
in detail in the Supplementary information.
Statistics
GraphPad prism was used for statistical analysis. Error
bars indicate mean values ± SEM of three independent
experiments unless stated otherwise. Student’s t test and
one-way ANOVA with Bonferroni post hoc tests were
conducted as indicated in the respective ﬁgures. p
values ≤ 0.05 were considered signiﬁcant unless otherwise
stated.
Results
Combination treatment of chondramide B and doxorubicin
inhibits tumor growth in vivo
The feasibility of using an actin polymerizer in cancer
treatment as a new therapeutic approach for combination
chemotherapy was evaluated in a xenograft mouse model.
For this purpose chondramide B (ChB) was used, since we
already had successfully used this compound in previous
in vivo studies30. Treatment regimes were established that
do not show an inﬂuence of single treatments on tumor
growth (Fig. 1a). In contrast, MDA-MB-231-bearing SCID
mice showed signiﬁcantly reduced tumor volume after
treatment with ChB and doxorubicin (Doxo) in combi-
nation (Fig. 1a). The combination therapy was well toler-
ated in vivo, indicated by the unaltered body weight of
treated mice (Fig. 1b). The tumor tissue was examined for
the proliferation marker Ki67 and in tendency showed
reduced proliferation rates (Fig. 1c), however, without
reaching statistical signiﬁcance. In vitro, MDA-MB-231
cells showed a synergistic cell death induction by low-dose
combination treatment (Fig. 1d). To analyze, whether the
enhanced cell death observed in MDA-MB-231 cells after
combination treatment is related to elevated DNA damage
levels, a comet assay was performed. Low-dose combina-
tion therapy led to increased DNA DSB levels in cells
compared to Doxo treatment alone (Fig. 1e), suggesting an
inﬂuence of ChB on Doxo-induced DNA damage.
Actin manipulation inhibits distinctive DSB repair
pathways
To investigate, whether the higher level of damaged
DNA after combination treatment is caused by additional
DNA damage induction, or an inhibition of DNA DSB
repair by ChB, the comet assay was performed with a
different set-up. Cells were treated with ChB or Doxo
alone or with the combination, followed by 4 h of repair
time (i.e. without Doxo) with or without additional ChB.
Treatment with the actin polymerizer ChB alone did not
induce DNA damage (Fig. 2a). However, addition of ChB
to the medium only during repair time increased DNA
damage levels (Fig. 2a). Thus, ChB impaired the repair of
Doxo-induced DNA damage. To examine whether the
observed reduced repair capacity can be attributed to
changes in actin states, we overexpressed actin mutants.
Actin mutant plasmids can be used as a tool to
either increase the G-actin pool (by using the poly-
merization defective mutantYFP-NLS-Beta-Actin-G13R)
or to increase the F-actin pool (by expressing the hyper-
polymerizing mutant YFP-NLS-Beta-Actin-S14C) in both
cytoplasm and nucleus of a cell. Interestingly, repair of
Doxo-induced DSBs was inhibited irrespective of whether
polymerization was inhibited or induced (Fig. 2b). This
ﬁnding could be veriﬁed by application of the classical
actin binders jasplakinolide (Jaspla), an actin polymerizer,
and the depolymerizer latrunculin B (LB), which both
inhibited successful repair of Doxo-induced DSBs
(Fig. 2c). The use of two further structurally unrelated
compounds (miuraenamide A, an actin polymerizer, and
Chivosazole A, an actin depolymerizer) showed similar
effects (Supplementary Fig. S1). Again, no increased DNA
damage could be detected with any actin compound alone
(Fig. 2b, c and Fig. S1). Hence, enhanced DSB levels after
combination treatment cannot derive from accumulation
of DNA damage by single compound treatment, but are
rather caused by defects in DNA damage repair due to
actin manipulation.
We used I-SceI-based reporter cell lines to study DSB
repair capacity of the four most important DSB repair
pathways NHEJ, alt-EJ, HDR, and SSA26 (Fig. 3a). All I-
SceI reporter cell lines express GFP-expression cassettes
that are interrupted by one or more recognition sites for
the endonuclease I-SceI. Transient overexpression of I-
SceI leads to one or more cuts in the GFP cassette. Suc-
cessful repair via the respective DNA repair pathway
restores the correct GFP sequence, resulting in expression
of functional GFP. Treatment with actin binders after
induction of DSBs by I-SceI overexpression led to differ-
ential responses. Actin polymerization by Jaspla and ChB
inhibited NHEJ, whereas LB did not reduce NHEJ efﬁ-
ciency (Fig. 3b). Alt-EJ was not inﬂuenced by any of the
applied actin-binding substances (Fig. 3b). In contrast,
both homology-dependent pathways, HDR and SSA, were
surprisingly impaired independently of the class of applied
actin binders (Fig. 3b). Manipulation of actin led to
inhibition of distinctive DSB repair pathways, suggesting a
multifaceted role of actin during DNA repair.
The state of nuclear actin is altered by doxorubicin
To evaluate if the inhibition of DNA repair is accom-
panied by a change in actin dynamics in the nucleus, we
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analyzed the state of nuclear actin before and after Doxo
treatment. HeLa cells expressing the nuclear actin-Chro-
mobody® (actin antibody fused to TagGFP and NLS)
showed pronounced nuclear actin aggregates upon Doxo
treatment (Fig. 4a, principle published in ref. 16), which
seem not to be identical to F-actin, since they are not
labeled by rhodamine-phalloidin (Fig. 4a). We performed
ﬂuorescence correlation spectroscopy (FCS) to measure
concentration and diffusion of free (i.e. mobile) actin in
the nucleus. Concentrations of free actin-GFP in the
nucleus were signiﬁcantly decreased in a time-dependent
manner upon Doxo-mediated DSB induction whereas
diffusion coefﬁcients remained at a similar value (Fig. 4b
and Supplementary Fig. S2). This indicates a transition of
nuclear actin from a mobile to an immobile (bound or
polymerized) state, since a nuclear export of actin-GFP
upon DSB induction was not detected in an independent
experiment based on ﬂuorescence intensity measure-
ments (Fig. 4c). We therefore hypothesize that the state of
nuclear actin is functionally important for DNA damage-
Fig. 1 Combination treatment of Doxo and ChB inhibits tumor growth. a−c MDA-MB-231 cells were injected into the ﬂank of SCID mice. Mice
were treated with Doxo or ChB alone or in combination, DMSO served as control (Ctrl). Tumor size was measured at the indicated time points and
tumor weight at the end of the experiment (a), mouse weight was observed at the indicated days (b). Ki67 staining was performed on parafﬁn-
embedded tumor sections and Ki67-positive cells quantiﬁed (n= 4). One representative staining per treatment group is shown; ×40 magniﬁcation,
scale bar 10 µm (c). d Cell death analysis was conducted with MDA-MB-231 by ﬂow cytometry analysis of YoPro-positive cells in triplicates (n= 3). e
T24 cells were treated with the indicated substances for 3 h and alkaline comet assay performed (n= 3). a (left), b two-way ANOVA, *p < 0.001. a
(right), c, d, e one-way ANOVA, *p < 0.05, ***p < 0.005. Scale bar 5 µm
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induced processes, and changes upon treatment with
Doxo.
Actin polymerization or depolymerization inhibits
recruitment of nuclear DNA damage repair factors
Due to the observed reorganization of nuclear actin
upon DNA damage induction, and the effect of actin
manipulation on speciﬁc DNA repair pathways, we
examined whether nuclear actin directly interacts with
speciﬁc DNA repair proteins.
NHEJ was inhibited by the actin-binding substances
Jaspla and ChB (Fig. 3b). The major key player for NHEJ is
DNA-PK, which is formed by binding of its catalytic
subunit DNA-PKcs to DNA-bound Ku70/80, leading to
its autophosphorylation and activation (Fig. 5a). Upon
Doxo treatment, foci formation of autophosphorylated
DNA-PK was signiﬁcantly reduced in cells treated with
Jaspla (Fig. 5b). A proximity ligation assay (Duolink®)
showed that nuclear actin is not directly bound to DNA-
PKcs under resting conditions or after stimulation with
Doxo (Fig. 5c), but to the respective recruitment protein
Ku70 under control conditions (Fig. 5d). This binding was
reduced upon DSB induction (Fig. 5d). Nuclear actin is
therefore directly associated with a subunit of DNA-PK
and, as a consequence, manipulation of actin might lead
to decreased DNA-PK activation. However, we were not
able to consistently show the interaction of actin and
Ku70 in a Co-IP approach (data not shown).
Interestingly, both HDR and SSA were affected by actin-
binding substances, whereas alt-EJ was not (Fig. 3b).
Hence, effects on key mediators that are shared by HDR
and SSA can be the cause for differential responses to
actin manipulation. Replication factor A (RPA) is com-
posed of three subunits (RPA-1/2/3) and its recruitment
to ssDNA is required for the initiation of both HDR and
SSA and for the inhibition of alt-EJ (Fig. 6a). Recruitment
of RPA-2 after Doxo-mediated damage induction was
diminished by LB and Jaspla, as demonstrated by the
presence of fewer RPA-2 foci in the nuclei (Fig. 6b), and a
decreased association of RPA-2 and chromatin (Fig. 6c).
RPA-2 was observed to be bound to nuclear actin under
control conditions and the binding was in tendency (but
Fig. 2 Actin manipulation inhibits repair of Doxo-induced DNA damage. a−c HeLa cells were treated with Doxo for 2 h, medium removed and
cells incubated in DMEM (repair time). Treatment without repair served as positive control, DMSO treatment as negative control. Alkaline comet assay
was performed with cells treated additionally with the indicated actin substances (a, c), or transfected with the indicated actin mutant plasmids (b).
Images were analyzed with OpenComet, ImageJ and relative tail moments calculated. Values normalized on Doxo repair samples, mean values of at
least three independent experiments are depicted. a, b, c one-way ANOVA, **p < 0.01, ***p < 0.005, ****p < 0.0001. a scale bar 5 µm, b upper panel
scale bar 7 µm, lower panel scale bar 3 µm
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not signiﬁcantly) decreased upon DSB induction, as
shown in a proximity ligation assay and coimmunopre-
cipitation (Fig. 6d, e), indicating a release of RPA-2 from
actin upon DNA damage. We performed structural
modeling of G-actin and consistently identiﬁed a con-
served site predicted to be part of a protein−protein
interaction interface in the vicinity of the residues Gly168
and Phe375. Global docking with subsequent local
reﬁnement offers several potential conformations for the
RPA-2/actin complex, where RPA-2 lies on the predicted
protein−protein interaction interface (Fig. 6f). In con-
clusion, we could show that nuclear actin is directly
involved in the recruitment of the DNA repair factor RPA
and that actin manipulation impairs RPA recruitment to
the site of DNA damage, resulting in an inhibition of the
RPA-dependent repair pathways HDR and SSA. Since
repair pathways are also linked to the cell cycle state, we
investigated cell cycle alterations by our treatment
regimes. Neither LB nor Jaspla caused any cell cycle arrest
at the concentrations used. Doxo itself caused a G2 arrest,
which was, however, not altered by the combination
treatment (Supplementary Fig. S3, left panel). Overall
transcription was transiently reduced after Doxo treat-
ment, but recovered during the repair phase. This process
was not altered in the presence of either Jaspla or LB
(Supplementary Fig. S3, right panel). General events
essential for DNA repair, like the activation of ATM-Chk2
pathway and local chromatin relaxation, were not altered
by actin targeting (Supplementary Fig. S4).
In order to investigate whether the observed effects are
limited to Doxo-induced DNA damage, we also tested
etoposide, cisplatin and irradiation in combination with
the actin-binding compounds. Etoposide-induced DNA
damage was very rapidly repaired in a complete manner,
irrespective of whether the actin compounds were present
or not (Supplementary Fig. S5). Levels of topoisomerase II
were also not changed by chondramide, jasplakinolide,
latrunculin B, Doxo or cisplatin (Supplementary Fig. S6),
indicating that topoisomerase is not the central player in
this context. DNA damage by cisplatin was quickly
repaired by HeLa cells. Latrunculin B signiﬁcantly inhib-
ited repair, while chondramide B or jasplakinolide only
showed a tendency to do so (Supplementary Fig. S7, upper
panel). However, formation of RPA-2 foci after treatment
Fig. 3 Actin-binding substances inhibit distinctive DSB repair pathways. a Schematics of all used reporter cell lines. b U2OS cells expressing one
of each reporter system were transfected with pcBASE and then cultivated with or without the indicated actin substances (LB [500 nM], Jaspla [50
nM], ChB [75 nM]) for 72 h. Percentages of GFP-positive cells were measured by ﬂow cytometry. Experiments performed in duplicates, mean values of
three independent experiments are shown, one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.005
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with cisplatin was signiﬁcantly inhibited by both latrun-
culin B and jasplakinolide (Supplementary Fig. S7, lower
panel). Finally, irradiation with 2 Gy also caused a DNA
damage, which was quickly repaired. Chondramide B,
jasplakinolide and latrunculin B all signiﬁcantly inhibited
DNA repair (Supplementary Fig. S8, upper panel) and
recruitment of RPA-2 (Supplementary Fig. S8, lower
panel)
Latrunculin B impairs repair of doxorubicin induced DSBs
in vivo
To assess whether repair of Doxo-induced DSBs can be
inhibited by additional treatment with actin binders also
in vivo, a murine tumor model was established with
4T1 cells (murine breast cancer). In vitro, the comet assay
revealed a stronger inhibition of repair in 4T1 cells by LB
than Jaspla (Fig. 7a), and demonstrates that the observed
effect also occurs in murine cells. Since LB was tolerated
well in mice if injected i.p. (Fig. 7b), an in vivo experiment
was performed with Doxo treatment of mice alone or in
combination with LB, and the extent of DNA damage was
determined in isolated tumor cells by comet assay. LB
alone did not show any effect, but in addition to the
chemotherapeutic Doxo led to a strong increase of
damaged DNA at subtoxic, tolerable concentrations
(Fig. 7c). To conclude, the impairment of DNA repair
factor recruitment by application of actin-binding sub-
stances leads to an enhancement of DNA damage levels
induced by chemotherapy in vivo and provides a new
approach for combination therapy.
Discussion
The existence of nuclear polymerized actin and its
function have been a matter of debate for many years in
cell biology31. Very recently it has turned out that actin is
involved in the repair of damaged DNA16–19. Actin is
currently hypothesized to be the substrate for clustering
and relocalization of DNA breaks during HDR18,19. The
aim of our study was to investigate whether this
mechanism can be modulated by actin-binding com-
pounds, and whether such compounds might be feasible
for combination therapy with DNA-damaging drugs like
Doxo.
Although latrunculin A has been reported to inhibit
yH2AX foci formation32, we did not observe the same
effect with LB or Jaspla at the low concentrations we used
Fig. 4 Doxo-induced DNA damage affects nuclear actin state. a HeLa cells were transfected with nuclear actin-Chromobody® and treated with
Doxo for 2 h. Cells positive for nuclear actin aggregates were counted. Mean values (n= 3) are depicted, scale bar 5 µm. b Images of actin-GFP
overexpressing HeLa cells were taken before and 1 h after addition of Doxo and ﬂuorescence intensity measured, scale bar 5 µm. Graph shows ratio
of measured intensities of nucleus to cytoplasm of up to 20 cells. c, d Cells overexpressing actin-GFP were treated with Doxo and single points FCS
measurements of nuclear actin were performed. Nuclear concentrations (panel c) of actin (c[nM)] and diffusion coefﬁcients (panel d) of nuclear actin
(D(µm2/s)) were determined in three independent experiments (up to 10 cells per experiment). a, b unpaired t test, two-tailed, ***p < 0.005. c, d one-
way ANOVA, ***p < 0.005, ****p < 0.0001
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(Supplementary Fig. S4). Therefore, general obstruction of
DNA damage seems not to be the cause of impaired DNA
repair upon targeting of actin. Also cell cycle status or
overall transcription are not inﬂuenced by the low con-
centrations of actin binders we used (Fig. S3). Conse-
quently, actin seems to directly inﬂuence speciﬁc DNA
repair factors. When using reporter cell lines as an
unbiased approach to detect changes in various repair
pathways due to the use of actin-binding compounds, we
made two surprising observations: First, not only the
homology-dependent pathways HDR and SSA were
affected, as was to be expected from previous work18,19,
but also NHEJ. This is of importance, since in cancer cells,
DSBs induced by Doxo are mainly repaired by NHEJ,
which thus represents a promising target for combination
chemotherapy. Furthermore, NHEJ is an attractive target,
since such an error-prone repair pathway will likely lead
to therapy-induced malignancies33,34. In this case, only
actin polymerizers (ChB and Jaspla) had an effect, in
contrast to latrunculin B (a depolymerizer). With our
proximity ligation assays we show that actin directly
interacts with Ku70 in the nucleus, but not with the cat-
alytic subunit of DNA-PK. Recruitment of the Ku70/80
heterodimer to the DSB is critical for the formation and
activation of DNA-PK. Actin manipulation signiﬁcantly
decreased autophosphorylation (i.e. activation) of DNA-
PK, highlighting the functional importance of the inter-
action of actin with the DNA-PK subunit Ku70. Andrin
et al. have previously demonstrated that Ku binds to F-
actin and that actin manipulation leads to perturbed
Fig. 5 Actin binders reduce DNA-PK autophosphorylation. a Simpliﬁed ﬂow chart of NHEJ. b Numbers of p-DNA-PK (T2609) foci were counted
and cells with at least 70 foci/nucleus deﬁned as positive cells, scale bars: 5 µm. c−e Duolink assay was performed according to the manufacturer’s
suggestions. Antibodies against actin and DNA-PKcs were used for Duolink assay (nuclear area is shown and nuclear outlines depicted in white) (c). d
Antibodies against actin and Ku70 were applied after treatment of cells with Doxo. Positive events were counted for each nucleus for at least three
independent experiments. b, d unpaired t test, two-tailed, *p < 0.05. NHEJ nonhomologous end joining
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retention of Ku80 at the DNA break15. The obvious
reduction of direct Ku7−actin interaction upon damage
induction we describe here might be due to a change of
conformation of the actin polymers after Doxo treatment:
these seem not to be regular F-actin ﬁlaments (no phal-
loidin binding), and might no longer be able to support
binding of Ku70. Interestingly, we have recently shown
that treatment of cells with an actin polymerizing com-
pound also elicits polymeric actin aggregates, which, in
contrast to F-actin ﬁlaments, are no longer able to bind
AMOT, a regulator of the YAP signaling pathway35. The
drop in mobile nuclear G-actin levels after Doxo without
any signs of nuclear export support the notion of actin
aggregation upon DNA damage.
The second important ﬁnding is that HDR and SSA are
inhibited by both manipulations that cause either actin
polymerization or depolymerization. This observation is
at ﬁrst view puzzling. However, it can be readily recon-
ciled with the recent ﬁndings that F-actin is mandatory for
HDR18,19: depolymerization by LB inhibits F-actin for-
mation, and, thus might hinder HDR, while Jasp causes
formation of actin aggregates, which are not functional for
DSB clustering, and, consequently could also inhibit HDR.
It has also been previously reported that treatment with
Jasp causes a decrease of nuclear actin dynamics as such36.
When we had a closer look at RPA-2, a protein which is of
central importance to HDR and SSA alike, we found that,
again, actin manipulation in both directions disrupted
recruitment of RPA-2 to DSB foci. In nuclear HeLa
extracts, RPA-3 had been previously suggested, but not
validated, as a potential binding partner of actin by Ser-
ebryannyy et al.37. We now give experimental evidence
that RPA-2 directly binds to nuclear actin in resting cells.
Interestingly, Doxo-mediated DSB induction dis-
assembled the nuclear RPA-2/actin interaction, most
likely again by the induction of actin polymers. It could be
speculated that RPA-2 is bound to a pool of nuclear G-
actin in the absence of acute DNA damage, and that
nuclear actin polymerization upon DSB induction is
necessary to release RPA and to subsequently enable its
recruitment to ssDNA. The observed inhibition of RPA-2
binding to actin by LB could be caused by allosteric effects
of LB, which have previously been reported to inhibit
binding of thymosin beta 4 to actin38. Interestingly, thy-
mosin binds to the same region of actin39 which is sug-
gested as binding site for RPA-2 in our docking model.
Since we no longer see a recruitment of RPA-2 to DSBs
after treatment with LB, we conclude that the existence of
polymeric actin structures at the DSBs is mandatory for
this process. For actin polymerizers we have recently
shown a trapping of proteins in the resulting actin
aggregates30,35. It could well be that RPA-2 shares a
similar fate and is trapped in actin aggregates upon
treatment with Jaspla, thus being no longer available for
recruitment to DSBs. In these aggregates and at the DSB
foci RPA-2 seems not to directly interact with actin, since
these structures are negative in the proximity ligation
assays. A graphic model of the suggested interactions of
actin with RPA-2 and its disturbance by actin-binding
compounds is depicted in Fig. 8. In therapeutical terms,
inhibition of HDR is an attractive option because tumors
with defects in HDR are often highly sensitive to DNA-
damaging therapy40.
Interestingly, repair of DNA damage after etoposide
treatment was not changed by actin-binding compounds.
This could be due to the fact that the damage by etoposide
is mainly mediated via inhibition of topoisomerase II, in
contrast to the more complex damage caused by Doxo.
Along this line, damage by irradiation, which is largely
independent of topoisomerase II, was repaired to a lower
degree in the presence of the actin binders. DNA damage
caused by cisplatin is mainly repaired by nucleotide
excision repair (NER)41. Since RPA-2 is also involved in
NER42, our ﬁnding that cisplatin-induced damage is
repaired to a lesser degree in the presence of actin binders
underscores our hypothesis.
All in all, the simultaneous inactivation of different DSB
repair mechanisms (NHEJ, HDR and SSA), as demon-
strated in this work, makes actin binders promising tools
for chemotherapy, as they target pathways that could
otherwise substitute for each other. Most importantly, the
observed DNA repair inhibition by application of actin-
(see ﬁgure on previous page)
Fig. 6 Recruitment of RPA-2 is inhibited upon actin manipulation. a Simpliﬁed ﬂow chart of RPA-mediated repair. b HeLa cells were treated with
the indicated substances for 2 h, followed by incubation in DMEM ± actin substances (repair). RPA foci were visualized by antibody staining and foci
of positive cells counted and normalized on nuclear area. At least 25 nuclei were analyzed for each sample (error bars ± SD, n= 3), scale bar 5 µm. c
Upon treatment, free RPA was extracted with extraction buffer, cells ﬁxed with 4% PFA and stained for RPA-2 and ﬂow cytometry performed
(performed in duplicates, n= 3). d Duolink assay was performed with antibodies against actin and RPA-2 after treatment of cells with Doxo (nuclear
area is shown and outlines depicted in white, scale bar 5 µm). Positive events were counted for each nucleus (n= 3). In total, at least 250 cells were
analyzed for each treatment condition. e Nuclear extracts were prepared from treated HeLa cells, immunoprecipitated with RPA-2 antibody and
immunoblotted for actin and RPA-2. Band densities were quantiﬁed and calculated as a ratio of actin intensity to RPA-2. Graph shows mean values (n
= 3) normalized on control. One exemplary blot is shown on the left. f Ten best-scoring docking poses for the RPA-2/actin complex. All proteins are
shown in ribbon representation. Additionally, semi-transparent surface of actin is shown, colored red and blue depending on whether a residue has
been predicted to lie on a protein−protein interaction interface by SPPIDER or not. Gly168 and Phe375 are shown in stick model. b, c, e one-way
ANOVA, *p < 0.05, **p < 0.01, ***p < 0.005. d unpaired t test, two-tailed, *p < 0.05
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binding substances could also be achieved in vivo by
tolerable, low doses of LB. So far, actin binders have not
yet found their way into clinical therapy due to the fear of
severe side effects. In our hands, DNA repair inhibition by
actin-binding substances was achieved by concentrations
below a cytotoxic threshold of the respective mono-
therapy. The issue of a rather narrow therapeutic window
of actin-binding substances in vivo, as published for jas-
plakinolide43, might therefore not be a problem when
actin binders are applied in low doses in a combination
therapy setting like ours. In addition to our ﬁndings,
previous reports on synergistic effects of actin-binding
compounds with cytotoxic drugs44,45, e.g. by inhibition of
efﬂux pumps make this approach even more promising.
Fig. 7 LB inhibits DNA repair in vivo. a Alkaline comet assay was performed in 4T1 cells as described above. b Mice were treated i.v. with Doxo in
combination with the indicated LB concentrations (i.p.) and mouse condition and weight observed for 48 h (two mice per condition). c Mice were
injected with 1 × 106 4T1 cells (s.c.) and tumors grown up to 9 days. Mice were then treated with the indicated substances for 24 h, tumor cells
isolated, and alkaline comet assay performed. Exemplary images are shown (scale bar 5 µm), values normalized on untreated mice (n= 11), *p < 0.05,
one-way ANOVA, Sidak’s multiple comparisons test
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As a consequence of this, we should bring actin binders
back into focus for future (pre-) clinical studies as they do
possess a high potential for the development of new
combination treatment strategies in cancer.
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